Seoochre

Many Pharma companies in EU suffer a size problem. When revenues are below 100 M€ is extremely difficult to survive in a market where to renew the portfolio is increasingly costly, as well as to pay the regulatory demands, which grow year by year (environmental regulations, verification, wastes processing, plastics control, etc...). Additionally, the easy solution of playing in the Generics Market does not work anymore, mostly due to the devastating price erosion in major markets (France, Germany, Italy and Spain). These companies use to be a family property and their operations do not exceed

A countless number of proteins including growth factors receptors, and cytokines play a pivotal role during the onset and exacerbation of numerous human diseases including cancer, autoimmune and inflammatory disorders.1

Of these proteins, extracellular and membrane-associated proteins represent around 40% of human proteome and they play diversified roles including signal transduction, cell adhesion, cell-cell interaction, and solute transport. Accordingly, the vast majority (ca. 60%) of current therapeutic approaches; such as small molecule inhibitors, oligonucleotide agents and monoclonal

Artificial intelligence is a field of engineering and science that focus on making intelligent machines. Artificial intelligence is a top technology that is reshaping the pharmaceutical industry's future. For ages, the pharmaceutical industry has been developing cures and treatments. Traditionally, medication design and manufacture took many years, extensive clinical studies, and sky-high prices.This has been changing with the advancement of 21st-century technology. We will see different drug designs, manufacturing, and clinical trials in the future.

Natural Language Processing (NLP), Mach

Medicine is the testament to the virtue of human innovation - a collective desire to reduce the burden of disease and an ever evolving journey to enhance the quality of human health. The origin of medicines can be traced back to ancient times when human began to use the natural resources to treat injuries and illness. Highly developed and documented evidences of medicinal practices comes from the world’s most ancient civilisations such as Egypt, India, China and Greece1. Traditional Chinese medicine2, which dates back more than 2,500 years, used a combination of herbs, acupuncture, and other

Traditional clinical trials have long served as the cornerstone of medical research, providing essential evidence for evaluating the safety and efficacy of new interventions. However, these trials often encounter significant challenges, including inefficiencies, high costs, logistical complexities, and limited participant diversity. Post the COVID-19 pandemic era, a groundbreaking approach called decentralized clinical trials (DCTs) has emerged as the new normal, harnessing technological advancements to revolutionize the landscape of medical research. This article explores the principles, key

Bacterial infections are responsible for a wide spectrum of diseases in humans causing significant morbidity and mortality on a global scale. Bacteria can survive in two different forms: free-living planktonic form and biofilm form. Bacterial biofilms are densely packed communities of bacterial cells which are surrounded by a self-produced polymeric matrix. It is reported that over 80% of microbial infections including many chronic diseases in humans are associated with biofilm. Apart from causing havoc in the form of deadly diseases, biofilm bacteria can make medical implants malfunctional o

Recent industry pressures brought on by the global COVID-19 pandemic provided critical lessons for the life sciences industry, and labs in particular, highlighting the urgent need for accelerated speed in bringing new medicines, vaccines and diagnostic testing services to market.

Before the pandemic hit, segments of the life sciences space, such as biopharma manufacturers, were slower to adopt new data management technology. Often working across legacy systems, companies needed to carefully orchestrate the acquisition, storage and analysis of their lab data across disparate sources to extr

Genomic medicine — the therapeutic use of cells and genetic materials — is at the center of a medical revolution. Approvals of genomic medicines are growing each year, fueled by new precision medicine platforms that target diseases without current effective treatments. Viral vectors, primarily adeno-associated virus (AAV), efficiently treat some diseases caused by monogenic mutations. Gene-modified cell therapies, notably CAR-T cell therapies, successfully treat some late-stage blood cancers but face obstacles for use with solid tumors. Challenges remain for both cell and gene therapies, incl

Treating disorders of the central nervous system (CNS) is notoriously challenging, particularly in the fields of psychiatry and neurology. Despite substantial investment, many drugs have failed to demonstrate efficacy in late phase clinical trials, leaving sponsors with few viable options for advancing their compounds, physicians struggling to decide which treatments to give to their patients, and patients in need of effective therapies. Digital biomarkers, which capture physiological and behavioural data have the potential to revolutionize CNS drug development and clinical practice. In this

Today there are more than 10,000 known rare diseases, defined by the European Union as conditions that affect less than 1 in 2,000 people and by the United States as those that affect fewer than 200,000 people. The vast majority of rare diseases are caused by or associated with detrimental mutations in protein-coding genes, making them prime candidates for correction with novel gene therapies and other gene-based medicines. Thanks to scientific advances in genetic engineering technologies over the last 20 years, clinical trials testing gene therapies and other gene-based medicines are more co

This article explores the transformative shift toward patient-centric clinical trials, emphasizing active patient involvement in study design, recruitment strategies, and the integration of Patient-Reported Outcomes (PROs). By prioritizing transparency, communication, and digital health technologies, patient-centric trials enhance engagement, streamline recruitment, and improve data quality. The approach holds the potential to accelerate drug development, but challenges like regulatory hurdles and data privacy concerns must be addressed collaboratively for widespread implementation.

This article explores the intricate relationship between Big Pharma and healthcare policies in the United States, unraveling the historical context, lobbying tactics, and policy impact. It delves into specific examples, such as the opioid crisis, and examines reform efforts amid public backlash. The influence on drug approval, pricing, and the role of patient advocacy groups are scrutinized, emphasizing the need for transparency and accountability. The article concludes by highlighting the complex challenges policymakers face in balancing innovation with public health.

Definition:The cold chain in the pharmaceutical industry refers to a temperature-controlled supply chain that ensures the integrity and efficacy of temperature-sensitive pharmaceutical products from the point of manufacture to the end-user. This specialized logistics system is designed to maintain specific temperature conditions throughout the entire distribution process, including storage, transportation, and handling.

Significance of the Cold Chain: The significance of the cold chain in the pharmaceutical industry cannot be overstated, especially when dealing with products that are sens

The pharmaceutical industry is expected to be worth $1.5 trillion by 2023, and the field of pharmacovigilance plays a crucial role in ensuring the safety of drugs. Artificial Intelligence (AI) and Machine Learning (ML) models are being applied to improve the pharmacovigilance process, including case intake using Optical Character Recognition (OCR) and Natural Language Processing (NLP), natural language generation (NLG) for narrative writing, robotic process automation (RPA) for dynamic case workflow, AI-based signal detection, and AI-based adverse event prediction. These advancements have the

There are many potential benefits that can be derived from IT outsourcing. Apart from cost savings, access to resources is also a driving force behind the outsourcing phenomena. With the right outsourcing partner enabling a flexible allocation of resources, IT projects can be scaled rapidly and affordably. Success or failure of outsourcing often has less to do with the provider and more to do with the customer. This is because discovery R&D organisations are rarely equipped to manage IT and have great difficulty specifying and implementing their goals. If any organisation has a poor track rec

While the life sciences sector has incrementally adopted digital technologies over the years, the rate of digital transformation over the next five years looks to be unprecedented. Collaborations and acquisitions in the pursuit of digital transformation have accelerated significantly. In 2018, US$9.5 billion was invested in the digital health sector over 698 deals. From the FDA approval of Otsuka’s sensor embedded drug Abilify Mycite and the approval of Pear Therapeutics’ app for the treatment of opioid abuse, through to Takeda’s partnership with Emulate Inc for the use of organs on chips for

The Scenario
With a lot of mergers and acquisitions taking place in the Asian markets, and growth being the primary objective of the Asian pharma industry, it has become evident that the centre-stage of global pharma operations is shifting from the U.S. and Europe to Asia.

Constrained with patent expiries and cost pressures, the big pharma is looking towards the Asian markets to offshore a variety of services from drug discovery to manufacturing.

The Voice
Pharma Focus Asia provides a unique opportunity to bring your products and services to the attention of key budget holders within

Big brands look forward to advertise in Pharma Focus Asia as it gives them the right audience they want to reach out to. PFA is read by senior management and key decision makers across top Pharma companies in Asia. Valued for our independent reporting and unbiased coverage on key topics of the industry, PFA is one of the most respected pharma magazines in Asia.

Leverage today, on our unparalleled reach to your target audience.

Our Services
Hand icon Magazine Advertisement
Hand icon Banner Advertisements
Hand icon e-Mail Direct Marketing

Functional service has been ranked high among the buzz words of the clinical research industry. Both sponsor organisations and service providers are equally excited about the opportunities this model offers and the potentially win-win situation it provides to them. Sponsor organisations typically send individual protocol-related service RFPs (request for proposals) to CROs and follow-up with contract negotiations. Sponsors have realised the benefits of reduced oversight and contract management a complete functional service outsourcing model offers saving valuable time and resources. Depending

2017 was the year where pharma realised that Big Data could dramatically increase the value of data produced during drug development or coming from Electronic Medical Records (EMRs) and medical devices. In 2018 it became clear that AI technologies could unlock much of the value of Big Data; 2019 is the year where we have everything in our hands to leverage Big Data, IoT and AI to deploy solutions that fundamentally affect the full drug development lifecycle, reverse the continuous growth of drug development timelines (25 per cent higher in 2018 versus 2012, reaching a startling 12 years on av